Approach to a kidney-transplant recipient with graft dysfunction: every timeframe, pre-renal, renal or post-renal, rejection or infection, step by step
Graft dysfunction = AKI in a single kidney on immunosuppression. Stabilise and dialyse if needed, then let time since transplant rank the causes, sort them pre-renal, post-renal, renal, exclude dehydration, obstruction and a high CNI level (Doppler + trough + BK/CMV PCR + DSA), and biopsy any persistent unexplained rise before treating rejection. Treat the biopsy, not the creatinine.
Watch & listen to this topic
⚡ NephroApp short · 2 min summary
🎧 Full podcast
🎧 Full podcast
Exam links & past questions
🎯 Asked in the real exam · 21 reports — answer each aloud
- Hyperacute rejection: treatment.
- Session 2 also included membranous nephropathy (25y, normal kidney, proteinuria 5g - investigations before biopsy then biopsy shows MN - treatment); and antibody-mediated rejection with tacrolimus level 4, month 6 - treatment.
- Q5: Stable transplant, slowly rising creatinine 1-2 years - approach
- ABMR: renal biopsy findings and treatment in order with doses (steroid then plasmapheresis then IVIG).
- Acute antibody-mediated rejection treatment plus diagnosis; and treatment of BK nephropathy (patient on Cellcept 2 gm, Tac level 9).
- Topic list: ABMR Rx; immunoglobulin side effects; Banff classification.
- Antibody-mediated rejection treatment regimen including steroid type; and how many plasma exchange sessions
- Transplant patient with rejection; biopsy shows tubulitis + interstitial inflammation, no C4d, no DSA — diagnosis and treatment
- Session 2: acute ABMR treatment; back pain + macro hematuria + proteinuria (DD renal vein thrombosis vs stone); hyponatremia 113 with malignancy/pleural effusion; criteria & causes of SIADH; SIADH Na 127 approach; early & late donor complications; EPS risk factors and treatment; indication for catheter removal; pregnant IgA nephropathy treatment (ACR >50, normal eGFR).
- Committee 2 list (4 Qs): ABMR; hyperkalemia; diabetic CKD with persistent albuminuria; hematuria in 70-year-old with glomerular source.
- T-cell-mediated rejection — Banff classification and treatment; allograft dysfunction 8 hours after operation.
- Committee 2: ABMR; Hyperkalemia; Diabetes CKD with persistent albuminuria; Hematuria in 70yo, glomerular source (4 questions). A colleague was asked about study supporting SGLT2 in CKD.
- Transplant patient with antibody-mediated rejection: Banff classification, C4d, and management.
- Difficult Tx/biopsy questions: (1) differentiate BK nephropathy vs acute AMR on biopsy; (2) Tx pt with BK infection + suspected rejection, no biopsy possible — management; (3) 30F fever + graft tenderness 1yr post-Tx, DDx & management; (4) CRRT citrate anticoagulation with filter clotting — action; (5) membranous nephropathy not responding to steroids, refusing cyclophosphamide/CNI — next option.
- Son potential kidney donor to father (ESRD); father has DSA MFI 4000 pre-Tx but crossmatch negative — approach? Accept donor? Desensitization protocol?
- Antibody-mediated rejection: renal biopsy findings; treatment in order with doses (steroid then plasmapheresis then IVIG).
- Transplant patient at 3 months with rising creatinine; biopsy = ABMR — risk factors for ABMR and treatment.
- Cellular rejection: pathognomonic histology and Banff classification; treatment for Banff 1
- Antibody-mediated acute rejection: treatment; do you use glucocorticoids and why
- Acute antibody-mediated rejection (AMR): diagnosis and management
- Transplantation: ABMR; management - donor-specific antibody daily (?) +++
🎯 Asked in the real exam · 9 reports — answer each aloud
- Delayed graft function (def; causes duration management).
- Acute graft dysfunction (early cpc) - differential dg.
- Anuria after 6 hours of kidney transplantation — your approach?
- Delayed graft function => cellular (rejection).
- What is delayed graft function and how to manage
- Transplant patient with rising creatinine - turned out to be CMV infection
- Delayed graft function: definition, causes, duration, management
- Acute graft dysfunction (early complications): differential diagnosis and management
- Creatinine rises 1 week after kidney transplantation: what is the cause?
🎯 Asked in the real exam · 6 reports — answer each aloud
- Commercial transplant abroad with creatinine 700 µmol/L and no donor or transplant data; Doppler normal, dialysis already started: what next?
- Transplant abroad, 48h later in ER with Cr 400 and anuria; biopsy = antibody-mediated rejection — urgent indication for dialysis, stabilize, then AMR management (plasma exchange, steroids, IVIG)
- Q8: KTX abroad 1 week ago, ER creat 200, stable - approach (Banff 2b, DSA)
- Commercial transplant patient from abroad (Uzbekistan), ~4-7 days post-op: approach to early graft dysfunction; pitfall of saying 'donor-specific antibody' when donor unknown; biopsy when platelets low.
- Patient who had illegal commercial transplant abroad (Pakistan), presents ~1 week post-op with creatinine 190, unknown baseline/donor/induction: approach to graft dysfunction (early post-transplant AKI).
- 35yo, transplant abroad (presumed commercial donor), presents day 5 post-transplant, no donor work-up, on steroid/MMF/tacrolimus, Cr 550: how to investigate and treat
Graft dysfunction at a glance
AKI in a single kidney on immunosuppression. Stabilise, rank by time, exclude reversible causes, then biopsy.
- Stabilise first Dialyse if needed; keep immunosuppression on.
- Time ranks causes Hours, week 1, 12 weeks, later.
- Sort the compartments Exclude volume, obstruction, high trough.
- Biopsy, then treat Treat the biopsy, not the creatinine.
-
Stop 1 · Emergency
Initial assessment and stabilisation
Treat the life threats; keep immunosuppression running.
- Hyperkalaemia, acidosis, overload, uraemia: urgent dialysis
- Gentle ultrafiltration, never aggressive
- Continue immunosuppression
HistoryAdherence, missed doses, new interacting drugs, diarrhoea, fever, urine output, donor and induction.
ExaminationVolume, graft tenderness, wound, drain, Foley.
Memory hook“Some Fluid Drains Through Plastic Bags”
Sstabilise FFoley + fluids DDoppler Ttrough PPCR + DSA Bbiopsy -
Stop 2 · Differential
Differential diagnosis by time since transplant
The clock ranks the causes before any test.
- Within 8 hours
- Hyperacute rejection, vascular thrombosis, primary non-function, ischaemia-reperfusion.
Doppler now; absent flow = re-exploration. - Week 1
- ATN/DGF (commonest), accelerated rejection, obstruction or leak, thrombosis, volume contraction.
- Up to 12 weeks
- Acute rejection, CNI toxicity, obstruction, pyelonephritis or viral infection, interstitial nephritis, recurrence (FSGS in the first month).
- 3–12 months
- BK nephropathy (peak 3–6 months), TCMR, CMV, TRAS, lymphocele.
- Over 1 year
- Non-adherence, de novo DSA → chronic active ABMR; chronic CNI toxicity, recurrent GN, TRAS, PTLD.
Memory hookTCMR: usually after week 1, most often within 3–6 months.
-
Stop 3 · Early graft
Day-1 oliguria and delayed graft function
Foley, fluids, Doppler; only then presumed ATN.
1 · Flush the Foley
Blocked or kinked catheter first.
2 · Fluid challenge
Reassess volume status.
3 · Renal Doppler
Thrombosis, obstruction or leak: urgent re-exploration or urologic intervention.
Artery thrombosis0.1–2%, within 72 h, painless anuria.
Vein: haematuria, oliguria, pain, no venous flow.DefinitionsDGF: dialysis within the first week.
Slow graft function: creatinine >3 mg/dL (~265 µmol/L), no dialysis.Presumed ATN
Continue immunosuppression, check trough, dialysis as needed; no aggressive UF.
Furosemide 100–200 mg only if hypervolaemic.Rising or beyond 1–2 weeks
Biopsy for rejection on ATN (most centres 7–10 days); send CMV PCR.
Exam trapStopping immunosuppression for DGF or dialysis: continue it.
-
Stop 4 · Exclusion
Pre-renal and post-renal causes
Exclude dehydration, obstruction and a high CNI level first.
Pre-renal- Hypovolaemia, sepsis: crystalloid (preferred to albumin), stop nephrotoxins.
- High trough: CNI vasoconstriction; find the CYP3A4 inhibitor, reduce.
- TRAS (1–23%, first year): Doppler → MRI → angioplasty ± stent.
Normal RI with falling urine output: haemodynamic cause.
Post-renal- Blocked or kinked Foley: flush.
- Ureteral obstruction (2–10%, within 3 months): ischaemic stricture commonest.
- Significant hydronephrosis: nephrostomy or stent → surgical reconstruction.
Perigraft collections
- Urine leak
- Fluid creatinine well above serum; first 3 months. Foley at once, drain, stent + Foley 1–3 weeks; cystogram before catheter out. Fails: nephrostomy, reimplant.
- Lymphocele
- Creatinine like serum; weeks to months; commoner with mTOR inhibitors. Drain if it compresses.
- Haematoma
- Early or after biopsy; usually resolves.
- Abscess
- Fever, CRP, positive culture: drain + antibiotics.
Exam trapMild hydronephrosis is often non-significant: the graft ureter has no valve; renogram first.
-
Stop 5 · Diagnosis
Renal causes and allograft biopsy
Persistent unexplained rise: biopsy before treating rejection (KDIGO 9.1, 6.1).
- Tacrolimus trough
- Urinalysis, culture, protein
- Plasma BK and CMV PCR
- DSA (anti-HLA screen if donor unknown)
- TMA screen: platelets, LDH, haptoglobin, film
- Doppler Resistive index
- ~0.6 normal, >0.7 high; rejection, ATN, thrombosis, hydronephrosis all raise it.
- Tacrolimus Trough
- High: toxicity likely. Low: missed doses or interaction, rejection risk.
- Typical targets: month 1 10–15, to ~6 months 8–12, later 6–8 (centre-dependent). True trough 12 ± 2 h post-dose.
- Plasma PCR BK virus
- >1,000 copies/mL beyond 2 weeks: probable.
>10,000: presumptive BK nephropathy. - Banff biopsy Lesions
- TCMR IA/IB: tubulitis + interstitial inflammation; intimal arteritis IIA/IIB; transmural III.
- Active ABMR: g+ptc + C4d, or g+ptc ≥2 + DSA; cg >0: chronic active.
- BK: SV40-positive inclusions. CNI: isometric vacuolisation; arteriolar hyalinosis, striped fibrosis.
Biopsy safety: platelets >100, PT and APTT <1.2 × control, BP <140/90, sterile urine.
Unsafe: correct first, or empirical pulse steroid if rejection likely.Exam trapHigh resistive index ≠ rejection: ATN, thrombosis and hydronephrosis raise it too.
-
Stop 6 · Treatment
Treatment of acute rejection
Treat the biopsy, not the creatinine; grade decides.
-
TCMR borderline with dysfunction, IA/IB
Methylprednisolone 3–5 mg/kg (250–500 mg) IV × 3–5 days; optimise trough and adherence; add MMF (Rec 6.5).
-
TCMR IIA–III or steroid-resistant
rATG 1–1.5 mg/kg × 7–14 days; IIA–III: start with pulse steroid + rATG.
After ATG: CMV and PJP prophylaxis, BK plasma PCR monitoring. -
Active ABMR
PLEX 2–5 + IVIG 100–200 mg/kg after each + pulse steroid.
Refractory, tertiary only: rituximab 375 mg/m² (RCT n=38 negative) or bortezomib 1.3 mg/m² × 4 (BORTEJECT negative).
Mixed: TCMR by grade + PLEX, IVIG, consider rituximab.
Chronic active ABMR: optimise tacrolimus, MMF, adherence; no proven reversal.
No response: repeat biopsy.No biopsy possibleE.g. platelets 20: methylprednisolone 500 mg × 3; correct platelets.
~60–70% respond within 5 days; no response: urgent biopsy or transfer.Unknown donorAnti-HLA antibody screen, not DSA; C4d substitutes on biopsy.
Screen HBV, HCV, HIV, TB.Memory hookTCMR = S-A-R: Steroid → ATG → Re-biopsy.
ABMR = PIS, then R, then B: PLEX + IVIG + Steroid → Rituximab → Bortezomib. -
-
Stop 7 · Infection and follow-up
Infection and late graft dysfunction
Infections need less immunosuppression; late loss starts with adherence.
-
BK nephropathy · Half, Halt, then CNI
Antimetabolite down ≥50% → no 10-fold fall at 4 weeks: stop it, prednisone 5–10 mg/day → lower CNI (trough ~5) → re-biopsy.
CNI-first equally acceptable (2024 BK consensus). IVIG, cidofovir, leflunomide unproven.
-
CMV disease
Valganciclovir 900 mg BID or IV ganciclovir 5 mg/kg q12h, GFR-adjusted; reduce antimetabolite.
Weekly PCR; no response after 2 weeks: UL97/UL54, maribavir 400 mg BID or foscarnet. -
Graft pyelonephritis
Fever, graft tenderness, pyuria: cultures, renally adjusted antibiotics, drain if obstructed.
Over 1 yearAdherence, trough, DSA, BK PCR, urine PCR, HbA1c, Doppler → biopsy with C4d, SV40, IF and EM.
PTLD: mass, weight loss, high LDH → CT, tissue biopsy.By biopsyChronic CNI toxicity: minimise CNI, never stop abruptly; mTOR inhibitor or belatacept (EBV-seropositive).
Recurrent GN: ACE inhibitor or ARB + specific: FSGS PLEX × 9; aHUS eculizumab; MN rituximab.eGFR still falling: plan dialysis access and early re-listing.
Exam trapPulse steroids for SV40-positive tubulitis: that is BK; reduce immunosuppression.
Fever with graft tenderness: graft pyelonephritis first; rejection rarely causes fever unless immunosuppression stopped. -
Rapid recall
Order of the work-up?
Stabilise → Foley + fluids → Doppler → trough → BK/CMV PCR, DSA → biopsy.
Causes within 8 hours?
Hyperacute rejection, thrombosis, primary non-function, ischaemia-reperfusion.
Delayed graft function?
Dialysis within the first week; biopsy if beyond ~1–2 weeks.
Urine leak or lymphocele?
Fluid creatinine well above serum: leak. Like serum: lymphocele.
Biopsy safety?
Platelets >100, PT and APTT <1.2 × control, BP <140/90.
Presumptive BK nephropathy?
Plasma PCR >10,000 copies/mL: antimetabolite down at least 50%.
TCMR IA/IB?
Methylprednisolone 250–500 mg × 3–5 days; resistant: rATG.
Active ABMR?
PLEX 2–5 + IVIG 100–200 mg/kg after each, pulse steroid.
Donor unknown?
Anti-HLA antibody screen, not DSA; C4d substitutes on biopsy.
Three rules for every ladder?
Keep immunosuppression on; treat the biopsy; no response = re-biopsy, recheck trough, BK, DSA.
Next tabs: algorithms, spoken answer, viva questions.
Sources: KDIGO transplant recipients 2009; Banff 2019 and 2022; CCN 2023 ch 109; 2024 BK consensus.
Spoken approach
say this aloud- Opening: This is graft dysfunction; I follow the KDIGO transplant-recipient chain: stabilise, exclude reversible causes, then biopsy before treating rejection.
- Stabilise: I treat hyperkalaemia, acidosis and overload and start dialysis if indicated, avoiding aggressive ultrafiltration; I continue immunosuppression.
- Time since transplant: Hours to week 1: thrombosis, hyperacute rejection, leak, ATN. Up to 12 weeks: acute rejection, CNI toxicity, obstruction, infection. Later: add chronic ABMR, TRAS, PTLD and non-adherence.
- History & exam: Adherence and missed doses, new interacting drugs, diarrhoea, fever, urine output, donor and induction; volume, graft tenderness, wound, drain and Foley.
- Pre- and post-renal: I flush the Foley, correct volume, and do Doppler ultrasound for thrombosis, stenosis, hydronephrosis and collections, sending drain creatinine if fluid leaks.
- Renal labs: Tacrolimus trough, urinalysis and culture, protein, plasma BK and CMV PCR, TMA screen and DSA, an anti-HLA screen if the donor is unknown.
- Diagnosis: Persistent unexplained rise: biopsy with C4d and SV40 once platelets are over 100; only now do I say TCMR, ABMR, BK, CNI toxicity or recurrence.
- Treatment & if it fails: TCMR: methylprednisolone 250-500 mg x 3-5 days, vascular or resistant: rATG. ABMR: plasma exchange + IVIG. BK: reduce immunosuppression. CMV: valganciclovir. No response: re-biopsy.
Quick reference
numbers at a glance| Order | Stabilise/dialyse → Foley + volume → Doppler → trough → BK/CMV PCR, DSA → biopsy |
| Hours (within 8 h) | Hyperacute rejection, vascular thrombosis, primary non-function, ischaemia-reperfusion |
| DGF | Dialysis within first week; biopsy if beyond ~1-2 weeks or creatinine rises |
| Artery thrombosis | 0.1-2%, within 72 h, painless anuria |
| Urine leak | Drain creatinine well above serum (often many times higher), lymphocele about equal to serum; Foley, stent 1-3 weeks |
| Tacrolimus target | Month 1: 10-15 • to ~6 months: 8-12 • later: 6-8 (typical; centre- and regimen-dependent) |
| BK | Peak 3-6 months; plasma PCR over 10,000 = presumptive → antimetabolite down at least 50% |
| TCMR | MP 3-5 mg/kg (250-500 mg) x 3-5 d → rATG 1-1.5 mg/kg x 7-14 d |
| ABMR | PLEX 2-5 + IVIG 100-200 mg/kg after each → rituximab 375 mg/m² |
| Biopsy safety | Platelets over 100; PT and APTT under 1.2 x control; BP under 140/90 |
◈
Exam traps & pitfalls
where marks are lost
- Jumping to biopsy before Foley, volume, Doppler and trough: KDIGO says exclude dehydration, obstruction and high CNI level first.
- Treating creatinine with pulse steroids without a biopsy when one is available (Rec 6.1).
- Stopping immunosuppression for DGF or for dialysis: continue it.
- Calling every fever with graft tenderness rejection: graft pyelonephritis is the leading cause.
- Pulsing steroids for SV40-positive tubulitis: that is BK, reduce immunosuppression.
- Saying DSA when the donor is unknown: say anti-HLA antibody screen; C4d substitutes on biopsy.
- Reading a high resistive index as rejection: it rises with ATN, thrombosis and hydronephrosis too.
- Over-treating mild hydronephrosis: the graft ureter has no valve; renogram if unclear.
- Forgetting non-adherence and interacting drugs as the trigger of late rejection.
Guideline algorithm
the source this answer followsSource: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients, Am J Transplant 2009;9(Suppl 3), Chapters 8 (p S27), 5 (p S19), 9 (p S30), 6 (p S21) and 13.1 (p S44), still the latest KDIGO transplant-recipient guideline; biopsy read by Banff 2019 Category 2 with the Banff 2022 additions; doses from Comprehensive Clinical Nephrology 2023 ch 109, Tables 109.1-109.2. This is the same verified chain used in our commercial-transplant, ABMR and TCMR topics. The time windows below are the graft-dysfunction-by-time differential from our TCMR topic.
| Step | What the guideline says |
|---|---|
| Rec 8.4 | We suggest including a kidney allograft ultrasound examination as part of the assessment of kidney allograft dysfunction. (2C) |
| Rec 5.1 | We recommend measuring CNI blood levels (1B), and suggest measuring at least … whenever there is a decline in kidney function that may indicate nephrotoxicity or rejection. (2C) |
| Ch 9 rationale | Causes of acute, reversible declines in GFR should be ruled out, including dehydration, urinary obstruction or acute CNI toxicity (by demonstrating high blood levels), before a biopsy is performed. |
| Rec 9.1 | We recommend kidney allograft biopsy when there is a persistent, unexplained increase in serum creatinine. (1C) |
| Rec 6.1 | We recommend biopsy before treating acute rejection, unless the biopsy will substantially delay treatment. (1C) |
| Rec 6.3 | We recommend corticosteroids for the initial treatment of acute cellular rejection. (1D) |
| Rec 6.3.2 | We suggest using lymphocyte-depleting antibodies or OKT3 for acute cellular rejections that do not respond to corticosteroids, and for recurrent acute cellular rejections. (2C) |
| Rec 6.4 | We suggest treating antibody-mediated acute rejection with one or more of the following alternatives, with or without corticosteroids (2C): plasma exchange; intravenous immunoglobulin; anti-CD20 antibody; lymphocyte-depleting antibody. |
| Rec 6.5 | For patients who have a rejection episode, we suggest adding mycophenolate if the patient is not receiving mycophenolate or azathioprine, or switching azathioprine to mycophenolate. (2D) |
| Rec 13.1.2 | We suggest reducing immunosuppressive medications when BKV plasma NAT is persistently greater than 10 000 copies/mL. (2D) |
| Time windows (TCMR topic) | Week 1 - acute tubular necrosis, hyperacute/accelerated rejection, obstruction or urine leak, renal artery or vein thrombosis, volume contraction; under 12 weeks - acute rejection, CNI toxicity, obstruction, pyelonephritis or viral infection, interstitial nephritis, recurrent disease; over 12 weeks - add chronic allograft nephropathy, transplant renal artery stenosis and PTLD. |
🧭
Algorithm 1 master approach diagram
graph TD;
A["Transplant recipient, creatinine rising or urine output falling"] --> B{"Hyperkalaemia, acidosis, overload or uraemia?"};
B -->|Yes| C["Urgent dialysis, gentle ultrafiltration, continue immunosuppression"];
B -->|No| D["Time since transplant ranks the causes, Algorithm 2"];
C --> D;
D --> E["Pre-renal: volume, sepsis, high CNI trough, vessels, Algorithm 3"];
D --> F["Post-renal: Foley, hydronephrosis, collection, leak, Algorithm 4"];
D --> G["Renal: trough, BK and CMV PCR, DSA, TMA screen, protein, Algorithm 6"];
E --> H{"Reversible cause found and creatinine back to baseline?"};
F --> H;
G --> H;
H -->|Yes| I["Treat the cause, recheck creatinine and trough"];
H -->|No, persistent unexplained rise| J["Graft biopsy with C4d and SV40, Banff"];
J --> K["Rejection, Algorithm 7"];
J --> L["Infection, BK or CMV, Algorithm 8"];
J --> M["CNI toxicity, TMA, recurrence, chronic injury, Algorithms 6 and 9"];
📌
Time since transplant
| Window | Think first | First move |
|---|---|---|
| Within 8 hours | Hyperacute rejection, vascular thrombosis, primary non-function, ischaemia-reperfusion injury | Doppler now; absent flow = surgeon, re-exploration |
| Week 1 | ATN/DGF (commonest), hyperacute/accelerated rejection, obstruction or urine leak, artery or vein thrombosis (artery within 72 h), volume contraction | Foley flush → fluid challenge → Doppler → biopsy if unexplained |
| Up to 12 weeks | Acute rejection (TCMR usually after week 1, most often within 3-6 months), CNI toxicity, obstruction (2-10%, within 3 months), urine leak (first 3 months), pyelonephritis or viral infection, interstitial nephritis, recurrent disease (FSGS in the first month) | Trough, Doppler, urine culture, BK/CMV PCR, DSA → biopsy |
| 3-12 months | BK nephropathy (over 90% within 12 months, peak 3-6 months), TCMR, CMV, TRAS (1-23%, usually first year), lymphocele | Plasma BK PCR, CMV PCR, Doppler for stenosis, biopsy |
| Over 1 year (late) | Non-adherence and de novo DSA → chronic active ABMR, chronic CNI toxicity, recurrent or de novo GN, TRAS, PTLD (median 18 months, graft 10-15%) | Adherence, trough, DSA, BK PCR, proteinuria → biopsy |
🧭
Algorithm 2 by time since transplant diagram
graph TD;
A["Graft dysfunction"] --> B{"Time since transplant"};
B -->|Within 8 hours| C["Hyperacute rejection, vascular thrombosis, primary non-function, ischaemia-reperfusion"];
C --> C1["Doppler now, absent flow means urgent surgical re-exploration"];
B -->|Week 1| D["ATN or DGF, accelerated rejection, obstruction or leak, thrombosis, volume contraction"];
D --> D1["Day-1 oliguria pathway, Algorithm 5"];
B -->|Up to 12 weeks| E["Acute rejection, CNI toxicity, obstruction, pyelonephritis or viral infection, interstitial nephritis, recurrent disease"];
E --> E1["Trough, Doppler, urine culture, BK and CMV PCR, DSA, then biopsy"];
B -->|3 to 12 months| F["BK nephropathy peak 3-6 months, TCMR, CMV, TRAS, lymphocele"];
F --> F1["Plasma BK PCR, CMV PCR, Doppler for stenosis, biopsy"];
B -->|Over 1 year| G["Non-adherence, de novo DSA, chronic active ABMR, chronic CNI toxicity, recurrence, TRAS, PTLD"];
G --> G1["Late pathway, Algorithm 9"];
📌
Pre renal renal post renal
| Bucket | Causes in a graft | Clue / test | Action |
|---|---|---|---|
| Pre-renal | Hypovolaemia, diarrhoea, sepsis, hypotension; CNI vasoconstriction (high trough); renal artery thrombosis; TRAS | Volume status, trough, Doppler; normal RI with falling urine output points to a haemodynamic cause | Crystalloid challenge, stop nephrotoxins, fix the trough; TRAS: Doppler then MRI, angioplasty +/- stent |
| Post-renal | Blocked or kinked Foley, ureteral obstruction (ischaemia up to 90%), urine leak, lymphocele or haematoma compressing the ureter | Foley flush, ultrasound (over 90% sensitive; mild hydronephrosis often non-significant), renogram, drain creatinine, cystogram | Foley, nephrostomy or stent, drain the collection, surgical repair if it fails |
| Renal - immunological | Hyperacute, TCMR, ABMR, mixed; recurrent GN | DSA (anti-HLA screen if donor unknown), proteinuria, biopsy with C4d | By Banff: steroids, ATG, PLEX + IVIG; disease-specific for recurrence |
| Renal - toxic | Acute or chronic CNI toxicity, CNI-associated TMA, interacting drugs (azoles, macrolides, non-DHP CCBs) | Trough, platelets, LDH, haptoglobin, film; biopsy: isometric vacuolisation, arteriolar hyalinosis, striped fibrosis | Reduce CNI to target; TMA: reduce or switch the agent |
| Renal - infective | Graft pyelonephritis, BK nephropathy, CMV, ATN | Urine and blood cultures, plasma BK PCR, CMV PCR, SV40 on biopsy | Antibiotics (drain if obstructed); BK: reduce immunosuppression; CMV: valganciclovir/ganciclovir |
🧭
Algorithm 3 pre renal and vascular diagram
graph TD;
A["Suspected pre-renal or vascular cause"] --> B["Volume status, BP, diarrhoea, sepsis, new drugs"];
B --> C{"Hypovolaemic?"};
C -->|Yes| D["Crystalloid fluid challenge, stop nephrotoxins, reassess urine output and creatinine"];
C -->|No| E["Tacrolimus trough and Doppler ultrasound"];
D --> E;
E --> F{"Trough above target for this phase?"};
F -->|Yes| G["CNI vasoconstriction or toxicity, look for CYP3A4 inhibitors, reduce dose, recheck"];
F -->|No| H{"Doppler finding"};
H -->|Absent flow within 72 hours, painless anuria| I["Renal artery thrombosis, urgent surgery"];
H -->|Haematuria, oliguria, pain, no venous flow| J["Renal vein thrombosis, urgent surgery"];
H -->|High velocity at anastomosis, first year| K["TRAS, MRI then angioplasty with or without stent"];
H -->|Normal| L["Not pre-renal, go to post-renal and renal pathways"];
🧭
Algorithm 4 post renal and collections diagram
graph TD;
A["Falling urine output or rising creatinine"] --> B["Check and flush Foley catheter"];
B --> C["Graft ultrasound with Doppler"];
C --> D{"Finding"};
D -->|Hydronephrosis| E{"Significant or mild?"};
E -->|Mild, graft ureter has no valve| F["Renogram before acting"];
E -->|Significant| G["Nephrostomy or ureteral stent, then find the cause, ischaemic stricture commonest"];
D -->|Perigraft collection| H["Aspirate or drain fluid, creatinine vs serum, culture"];
H -->|Fluid creatinine well above serum| I["Urine leak, Foley at once, cystogram or renogram"];
I --> I1["Low volume: stent plus Foley 1-3 weeks and drain, high volume or failure: explore and reimplant"];
H -->|Creatinine like serum, weeks to months| J["Lymphocele, drain if it compresses ureter or vessels"];
H -->|Blood, early or after biopsy| K["Haematoma, usually resolves"];
H -->|Fever, CRP, positive culture| L["Abscess, drain plus antibiotics"];
D -->|Normal| M["Renal pathway, Algorithm 6"];
🧭
Algorithm 5 day 1 oliguria and dgf diagram
graph TD;
A["Day-1 oliguria or anuria after transplant"] --> B["Check and flush Foley catheter"];
B --> C{"Still oliguric?"};
C -->|Yes| D["Fluid challenge, reassess volume status"];
D --> E{"Still oliguric?"};
E -->|Yes| F["Renal Doppler ultrasound, vascular and urologic causes"];
F --> G{"Thrombosis, obstruction or leak?"};
G -->|Yes| H["Urgent surgical re-exploration or urologic intervention"];
G -->|No| I["Presumed ATN, delayed graft function if dialysis needed in week 1"];
I --> J["Continue immunosuppression, check CNI trough, dialysis as needed"];
J --> K{"Creatinine falling over days?"};
K -->|Yes| L["Supportive care, await recovery over days to weeks"];
K -->|No, rising or beyond 1-2 weeks| M["Biopsy for rejection on ATN, send CMV PCR"];
🧭
Algorithm 6 renal causes and biopsy diagram
graph TD;
A["Pre- and post-renal excluded"] --> B["Tacrolimus trough, urinalysis and culture, protein, plasma BK PCR, CMV PCR, DSA, platelets, LDH, haptoglobin, film"];
B --> C{"Clue"};
C -->|High trough| D["Reduce CNI to target, recheck creatinine, biopsy if no improvement"];
C -->|BK PCR over 10,000 or rising| E["BK pathway, Algorithm 8"];
C -->|CMV PCR positive with fever, leukopenia| F["CMV pathway, Algorithm 8"];
C -->|Low platelets, high LDH, schistocytes| G["TMA, CNI-related or antibody-mediated, biopsy"];
C -->|New heavy proteinuria| H["Recurrent or de novo GN, biopsy with IF and EM"];
C -->|Positive DSA or no clue| I["Biopsy"];
D --> I;
I --> J{"Safe to biopsy? Platelets over 100, PT and APTT under 1.2 x, BP under 140/90"};
J -->|Yes| K["Graft biopsy with C4d and SV40, Banff scoring"];
J -->|No| L["Correct first, or empirical pulse steroid if rejection likely, biopsy when safe"];
🪜
How to read the tests
| Finding | Meaning |
|---|---|
| Absent or reversed diastolic flow, no venous flow | Vascular thrombosis or severe rejection: urgent surgical review |
| Resistive index | About 0.6 normal, above 0.7 high; rejection, ATN, thrombosis and hydronephrosis all raise it, so it does not say which |
| High tacrolimus trough | CNI toxicity likely: reduce and recheck; a true trough is 12 +/- 2 h after a twice-daily dose |
| Low or undetectable trough | Missed doses or interaction: rejection risk is high |
| Plasma BK PCR | Over 1,000 copies/mL sustained beyond 2 weeks = probable; over 10,000 = presumptive BK nephropathy |
| Biopsy: tubulitis + interstitial inflammation, no C4d/DSA | TCMR IA/IB; intimal arteritis (v1/v2) = IIA/IIB; transmural arteritis = III |
| Biopsy: microvascular inflammation (g+ptc) + C4d or g+ptc at least 2 + DSA | Active ABMR; with transplant glomerulopathy (cg over 0) = chronic active ABMR |
| Biopsy: intranuclear inclusions, SV40 positive | BK nephropathy: reduce immunosuppression, do not pulse steroids |
| Biopsy: isometric tubular vacuolisation / arteriolar hyalinosis, striped fibrosis | Acute / chronic CNI toxicity |
| Biopsy: same lesion as the native kidney | Recurrent disease (FSGS, IgAN, MN, C3G, aHUS) |
🧭
Algorithm 7 rejection treatment diagram
graph TD;
A["Biopsy shows rejection"] --> B{"Type"};
B -->|TCMR borderline with dysfunction or grade IA, IB| C["Methylprednisolone 250-500 mg IV daily x 3-5 days, optimise trough and adherence, add MMF"];
B -->|TCMR grade IIA, IIB or III| D["Pulse steroid plus rATG 1-1.5 mg/kg x 7-14 days"];
B -->|Active ABMR| E["Plasma exchange 2-5 sessions plus IVIG 100-200 mg/kg after each, plus pulse steroid"];
B -->|Mixed| F["Treat TCMR by grade plus plasma exchange, IVIG, consider rituximab"];
B -->|Chronic active ABMR| G["Optimise tacrolimus and MMF, adherence, no proven reversal"];
C --> H{"Creatinine improving?"};
D --> H;
E --> H;
H -->|Yes| I["Daily creatinine, CMV and PJP prophylaxis after ATG, BK plasma PCR monitoring, fix the trigger"];
H -->|No| J["Repeat biopsy, grade III or antibody component?"];
J --> K["Steroid-resistant TCMR: rATG, refractory ABMR: rituximab 375 mg/m2 or bortezomib in tertiary centre, both negative in RCTs"];
🧭
Algorithm 8 infection BK CMV pyelonephritis diagram
graph TD;
A["Graft dysfunction with infection clue"] --> B{"Which picture?"};
B -->|Fever, graft tenderness, pyuria| C["Graft pyelonephritis until proven otherwise"];
C --> C1["Urine and blood cultures, ultrasound for obstruction or abscess, renally adjusted antibiotics, drain if obstructed"];
C --> C2["Ask about stopped immunosuppression, rejection rarely causes fever otherwise"];
B -->|Asymptomatic rise, months 3-12, BK viraemia| D["Plasma BK PCR, biopsy two cores with medulla, SV40"];
D --> D1["Antimetabolite down at least 50%, recheck plasma PCR, expect a 10-fold fall by 4 weeks"];
D1 --> D2["No 10-fold fall at 4 weeks: stop antimetabolite, prednisone 5-10 mg/day, then lower CNI, tacrolimus trough about 5"];
D2 --> D3["Still rising: confirm reduction achieved, re-biopsy, no proven antiviral"];
B -->|Fever, leukopenia, diarrhoea, after ATG or D+/R-| E["Quantitative CMV PCR, endoscopy and biopsy if GI and PCR negative"];
E --> E1["Valganciclovir 900 mg twice daily, or IV ganciclovir 5 mg/kg q12h if severe, GFR-adjusted, reduce antimetabolite"];
E1 --> E2["Weekly PCR, at least 2 weeks until below threshold"];
E2 --> E3["No response after 2 weeks: UL97 and UL54 genotyping, maribavir 400 mg twice daily or foscarnet"];
🧭
Algorithm 9 late graft dysfunction diagram
graph TD;
A["Over 1 year: slow creatinine rise or new proteinuria"] --> B["Adherence, pill count, trough history, new drugs"];
B --> C["Doppler for obstruction and TRAS, trough, plasma BK PCR, DSA, urine PCR, HbA1c"];
C --> D["Graft biopsy with C4d, SV40, IF and EM"];
D --> E{"Biopsy"};
E -->|Chronic active ABMR| F["Optimise tacrolimus, MMF and steroid, adherence support"];
E -->|Chronic CNI toxicity| G["Minimise CNI, consider mTOR inhibitor or belatacept if EBV positive"];
E -->|Recurrent or de novo GN| H["ACE inhibitor or ARB plus disease-specific therapy"];
E -->|BK nephropathy| I["Stepwise immunosuppression reduction"];
C -->|Mass, weight loss, high LDH| J["PTLD work-up, CT, tissue biopsy"];
F --> K{"eGFR still falling?"};
G --> K;
H --> K;
K -->|Yes| L["Plan dialysis access and early re-listing"];
🧭
Algorithm 10 unknown donor or no biopsy diagram
graph TD;
A["Commercial transplant abroad or no biopsy access"] --> B["Stabilise, dialyse if needed, continue immunosuppression"];
B --> C["Doppler, tacrolimus trough, BK, CMV, HBV, HCV, HIV, TB screen"];
C --> D["Anti-HLA antibody screen, not DSA, because the donor is unknown"];
D --> E{"Biopsy possible and safe?"};
E -->|Yes| F["Biopsy, C4d substitutes for DSA in Banff"];
E -->|No, for example platelets 20| G["Methylprednisolone 500 mg IV daily x 3, correct platelets"];
G --> H{"Response by about 5 days?"};
H -->|Yes| I["Optimise maintenance, still biopsy when safe"];
H -->|No| J["Urgent biopsy or transfer, ATG for resistant TCMR, PLEX plus IVIG for ABMR"];
📌
Treatment by cause
| Cause | First-line | If it fails |
|---|---|---|
| Hypovolaemia | Crystalloid (preferred to albumin); stop nephrotoxins | Look again: Doppler, trough |
| DGF / ATN | Continue immunosuppression, dialysis as needed, avoid aggressive UF; furosemide 100-200 mg only if hypervolaemic | Biopsy if beyond ~1-2 weeks or rising creatinine (most centres at 7-10 days) |
| Artery / vein thrombosis | Urgent surgical re-exploration | Graft lost: back to dialysis, taper immunosuppression |
| Urine leak | Foley at once, drain collection, stent + Foley 1-3 weeks; cystogram before catheter out | Nephrostomy, then explore and reimplant |
| Obstruction | Nephrostomy or stent | Surgical urinary reconstruction |
| TRAS | Doppler then MRI, angioplasty +/- stent | Transplant surgeon and interventional radiology review |
| CNI toxicity | Reduce to target trough, remove the interacting drug; titrate, never stop abruptly | mTOR inhibitor or belatacept (EBV-seropositive) |
| CNI-associated TMA | Reduce or switch the offending CNI | CNI-free regimen |
| TCMR IA/IB, borderline with dysfunction | Methylprednisolone 3-5 mg/kg (250-500 mg) x 3-5 days | rATG 1-1.5 mg/kg x 7-14 days |
| TCMR IIA-III | Pulse steroid + rATG; valganciclovir prophylaxis 6 weeks after | Repeat biopsy |
| Active ABMR | PLEX 2-5 sessions + IVIG 100-200 mg/kg after each, pulse steroid | Rituximab 375 mg/m² (largest RCT n=38 negative); bortezomib 1.3 mg/m² x 4 (BORTEJECT RCT negative), tertiary only |
| BK nephropathy | Antimetabolite down at least 50% → stop it, with prednisone 5-10 mg/day → lower CNI (tacrolimus trough about 5); reducing the CNI first is equally acceptable (2024 BK consensus) | Confirm reduction, re-biopsy; IVIG, cidofovir, leflunomide unproven |
| CMV disease | Valganciclovir 900 mg BID or IV ganciclovir 5 mg/kg q12h, GFR-adjusted; reduce antimetabolite | UL97/UL54 → maribavir 400 mg BID or foscarnet |
| Graft pyelonephritis | Cultures, renally adjusted antibiotics, drain if obstructed | Image for obstruction, ureteric stricture or abscess |
| Recurrent FSGS | Plasma exchange x 9, CNI, steroid, ACE inhibitor, no mTOR inhibitor | Rituximab 500 mg weekly x 4 or cyclophosphamide |
| Recurrent aHUS / MN | Eculizumab / rituximab | Specialist centre |
⤴
Memorise treatment and escalation
Order of the work-up — Some Fluid Drains Through Plastic Bags: Stabilise (dialyse if needed, keep immunosuppression) → Foley flush + fluids → Doppler → Trough → PCR (BK, CMV) + DSA panel → Biopsy.
Causes and their ladders — the 6 Ps (first move → if it fails → last resort):
- Perfusion (pre-renal): crystalloid, stop nephrotoxins → look again: Doppler and trough. TRAS: Doppler → MRI → angioplasty ± stent.
- Pipes (surgical): thrombosis re-explore → graft lost: dialysis, taper immunosuppression. Leak Foley + drain + stent 1-3 weeks → nephrostomy → reimplant. Obstruction nephrostomy or stent → surgical reconstruction.
- Poison (CNI): trim to target trough and remove the interacting drug, never stop abruptly → switch to mTOR inhibitor or belatacept (EBV-seropositive). CNI-TMA: reduce or switch → CNI-free.
- Police (rejection) — biopsy first:
- TCMR = S-A-R: Steroid pulse (MP 250-500 mg x 3-5 d) → ATG (1-1.5 mg/kg x 7-14 d) → Re-biopsy. Grade IIA-III: start at steroid + ATG.
- ABMR = PIS, then R, then B: PLEX 2-5 + IVIG after each + Steroid → Rituximab → Bortezomib (tertiary only; both were negative in RCTs).
- Pathogens (infection):
- BK = Half, Halt, then CNI: antimetabolite down at least 50% → no 10-fold fall at 4 weeks: stop it (prednisone 5-10 mg/day to avoid CNI monotherapy) → lower the CNI (tacrolimus trough about 5) → re-biopsy.
- CMV = Val/Gan, cut, check resistance: valganciclovir or IV ganciclovir + reduce antimetabolite → UL97/UL54 → maribavir or foscarnet.
- Pyelonephritis: cultures + antibiotics + drain if obstructed → image for stricture or abscess.
- Past disease (recurrence): FSGS plasma exchange → rituximab or cyclophosphamide; aHUS eculizumab; MN rituximab.
Three rules that cover every ladder: keep immunosuppression on (DGF and dialysis included) • treat the biopsy, not the creatinine • no response = re-biopsy and re-check trough, BK and DSA.
🎓
Examiner follow-ups
tap to reveal · self-test
Q1A transplant recipient has a rising creatinine. What is your approach?reveal
Q2What causes graft dysfunction within 8 hours of surgery?reveal
Q3Fresh transplant, good urine output, then oliguria on day 1. What do you do?reveal
Q4Define delayed graft function and slow graft function.reveal
Q5How do you tell a urine leak from a lymphocele?reveal
Q6Tacrolimus 16 at month 4 with creatinine 180 from 90. Is it toxicity?reveal
Q7Fever and graft tenderness one year after transplant?reveal
Q8How do you differentiate BK nephropathy from TCMR on biopsy, and why does it matter?reveal
Q9Biopsy shows Banff IIB TCMR. Treatment?reveal
Q10Active ABMR on biopsy. Treatment and evidence?reveal
Q11You cannot biopsy (platelets 20 or no access). What do you do?reveal
Q12Commercial transplant abroad, unknown donor. What do you not say?reveal
Q13Ten years out, slow creatinine rise and proteinuria. What are you thinking?reveal
Q14When is the graft biopsy safe?reveal
📌
Go deeper
Each pathway has its own full case on NephroApp:
- Delayed graft function / day-1 oliguria
- Early surgical complications and urine leak
- CNI toxicity and tacrolimus level problems
- T-cell-mediated rejection and antibody-mediated rejection
- Suspected rejection with no biopsy and commercial transplant abroad
- BK virus nephropathy and CMV in transplant
- Recurrent glomerular disease and PTLD